Two Cysteines in Raf Kinase Inhibitor Protein Make Differential Contributions to Structural Dynamics In Vitro

Area of Science:

• Biochemistry
• Molecular Biology
• Structural Biology

Background:

• Raf kinase binding protein (RKIP) is a scaffolding protein regulating key cellular pathways like the Raf-MEK-ERK cascade.
• RKIP acts as a negative regulator, making it a potential therapeutic target for cancer.
• The mechanism behind RKIP's transition between monomeric and dimeric forms, and its impact on binding partners, remains unclear.

Purpose of the Study:

• To elucidate the role of cysteine 133 in the structural dynamics and dimerization of recombinant human RKIP (rhRKIP).
• To investigate the potential of targeting RKIP dimerization for cancer therapy.

Main Methods:

• Purification of recombinant human RKIP (rhRKIP) from Escherichia coli.
• Site-directed mutagenesis of cysteine 133 to alanine or serine.
• Dynamic light scattering and liquid chromatography (LC) quadrupole time-of-flight (Q-TOF) mass spectrometry (MS) for structural analysis.
• LC-MS/MS for peptide identification.
• Assessment of cancer cell viability upon treatment with RKIP-mimicking peptides.

Main Results:

• Mutation of cysteine 133 did not alter biochemical characteristics but influenced solution behavior.
• Dynamic light scattering and LC-MS/MS confirmed the role of cysteine 133 in rhRKIP dimerization.
• A 32-amino acid peptide mimicking the dimerization interface abrogated rhRKIP dimer formation.
• The peptide and its derivatives showed effects on cancer cell viability.

Conclusions:

• Cysteine 133 is critical for regulating RKIP structural dynamics and dimerization.
• Controlling RKIP dimerization, potentially with reducing agents or specific peptides, could offer a novel strategy for targeting cancer cells.